Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q39328882)
Watch
English
Cyclotherapy: opening a therapeutic window in cancer treatment
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
title
Cyclotherapy: opening a therapeutic window in cancer treatment
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
author name string
Ingeborg M M van Leeuwen
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
language of work or name
English
0 references
publication date
1 June 2012
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
published in
Oncotarget
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
volume
3
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
issue
6
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
page(s)
596-600
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
cites work
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Systematic identification of genomic markers of drug sensitivity in cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Fasting and differential chemotherapy protection in patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Translating p53 into the clinic.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Identification of nuclear export inhibitors with potent anticancer activity in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
A history of cancer chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Analysis of FDA approved anticancer drugs reveals the future of cancer therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Cyclotherapy: protection of normal cells and unshielding of cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Exploiting cancer cell cycling for selective protection of normal cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Essential drugs for cancer therapy: a World Health Organization consultation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
11 September 2017
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
14 September 2017
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
14 September 2017
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
14 September 2017
Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
14 September 2017
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
14 September 2017
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
14 September 2017
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
25 September 2017
Timeline: Chemotherapy and the war on cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
15 June 2018
Protecting normal cells from the cytotoxicity of chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3442291
retrieved
21 August 2018
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22711025
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Cell lines battle cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22711025
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22711025
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.18632/ONCOTARGET.524
0 references
PMCID
3442291
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
PubMed ID
22711025
1 reference
stated in
Europe PubMed Central
PMCID
3442291
retrieved
11 September 2017
ResearchGate publication ID
227342920
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit